|
1
|
Gansler T, Ganz PA, Grant M, Greene FL,
Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et
al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J
Clin. 60:345–350. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vijayvergia N and Mehra R: Clinical
challenges in targeting anaplastic lymphoma kinase in advanced
non-small cell lung cancer. Cancer Chemother Pharmacol. 74:437–446.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Verkhivker GM: Exploring
sequence-structure relationships in the tyrosine kinome space:
Functional classification of the binding specificity mechanisms for
cancer therapeutics. Bioinformatics. 23:1919–1926. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yin S, Zhou L, Lin J, Xue L and Zhang C:
Design, synthesis and biological activities of novel
oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR inhibitors.
Eur J Med Chem. 101:462–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiong X, Liu H, Fu L, Li L, Li J, Luo X
and Mei C: Antitumor activity of a new N-substituted thiourea
derivative, an EGFR signaling-targeted inhibitor against a panel of
human lung cancer cell lines. Chemotherapy. 54:463–474. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dickler MN, Cobleigh MA, Miller KD, Klein
PM and Winer EP: Efficacy and safety of erlotinib in patients with
locally advanced or metastatic breast cancer. Breast Cancer Res
Treat. 115:115–121. 2009. View Article : Google Scholar
|
|
9
|
Fraunfelder FT, Sciubba JJ and Mathers WD:
The role of medications in causing dry eye. J Ophthalmol.
2012:2858512012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson KS, Levin F and Chu DS: Persistent
corneal epithelial defect associated with erlotinib treatment.
Cornea. 28:706–707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morishige N, Hatabe N, Morita Y, Yamada N,
Kimura K and Sonoda KH: Spontaneous healing of corneal perforation
after temporary discontinuation of erlotinib treatment. Case Rep
Ophthalmol. 5:6–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saint-Jean A, Sainz de la Maza M, Morral
M, Morral M, Torras J, Quintana R, Molina JJ and Molina-Prat N:
Ocular adverse events of systemic inhibitors of the epidermal
growth factor receptor: Report of 5 cases. Ophthalmology.
119:1798–1802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barabino S, Chen W and Dana MR: Tear film
and ocular surface tests in animal models of dry eye: Uses and
limitations. Exp Eye Res. 79:613–621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Romay C, Armesto J, Remirez D, González R,
Ledon N and García I: Antioxidant and anti‑inflammatory properties
of C‑phycocyanin from blue-green algae. Inflamm Res. 47:36–41.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Z, Yang WZ, Zhu ZZ, Hu QQ, Chen YF,
He H, Chen YX and Liu ZG: Therapeutic effects of topical
doxycycline in a benzalkonium chloride-induced mouse dry eye model.
Invest Ophthalmol Vis Sci. 55:2963–2974. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lemp MA: Report of the national eye
institute/industry workshop on clinical trials in dry eyes. Clao J.
21:221–232. 1995.PubMed/NCBI
|
|
17
|
Williams KA, Standfield SD, Smith JR and
Coster DJ: Corneal graft rejection occurs despite Fas ligand
expression and apoptosis of infiltrating cells. Br J Ophthalmol.
89:632–638. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carey KD, Garton AJ, Romero MS, Kahler J,
Thomson S, Ross S, Park F, Haley JD, Gibson N and Sliwkowski MX:
Kinetic analysis of epidermal growth factor receptor somatic mutant
proteins shows increased sensitivity to the epidermal growth factor
receptor tyrosine kinase inhibitor, erlotinib. Cancer Res.
66:8163–8171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Minna JD and Dowell J: Erlotinib
hydrochloride. Nat Rev Drug Discov. (Suppl): S14–S15.
2005.PubMed/NCBI
|
|
20
|
The definition and classification of dry
eye disease: Report of the Definition and Classification
Subcommittee of the International Dry Eye WorkShop (2007). Ocul
Surf. 5:75–92. 2007. View Article : Google Scholar
|
|
21
|
Stapleton F, Alves M, Bunya VY, Jalbert I,
Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, et
al: TFOS DEWS II Epidemiology Report. Ocul Surf. 15:334–365. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bose T, Diedrichs-Möhring M and Wildner G:
Dry eye disease and uveitis: A closer look at immune mechanisms in
animal models of two ocular autoimmune diseases. Autoimmun Rev.
15:1181–1192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu NN, Liu L, Li J and Sun YZ: Prevalence
of and risk factors for dry eye symptom in mainland china: A
systematic review and meta-analysis. J Ophthalmol. 2014:7486542014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ou SI, Govindan R, Eaton KD, Otterson GA,
Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, et al:
Phase I results from a study of crizotinib in combination with
erlotinib in patients with advanced nonsquamous non-small cell lung
cancer. J Thorac Oncol. 12:145–151. 2017. View Article : Google Scholar
|
|
25
|
Wang L, Wu X, Shi T and Lu L: Epidermal
growth factor (EGF)-induced corneal epithelial wound healing
through nuclear factor κB subtype-regulated CCCTC binding factor
(CTCF) activation. J Biol Chem. 288:24363–24371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huo YN, Chen W and Zheng XX: ROS, MAPK/ERK
and PKC play distinct roles in EGF-stimulated human corneal cell
proliferation and migration. Cell Mol Biol (Noisy-le-grand).
61:6–11. 2015.
|
|
27
|
Nakamura Y, Sotozono C and Kinoshita S:
The epidermal growth factor receptor (EGFR): Role in corneal wound
healing and homeostasis. Exp Eye Res. 72:511–517. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du H, Hu Z, Bazzoli A and Zhang Y:
Prediction of inhibitory activity of epidermal growth factor
receptor inhibitors using grid search-projection pursuit regression
method. PLoS One. 6:e223672011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wilson SE, He YG and Lloyd SA: EGF, EGF
receptor, basic FGF, TGF beta-1, and IL-1 alpha mRNA in human
corneal epithelial cells and stromal fibroblasts. Invest Ophthalmol
Vis Sci. 33:1756–1765. 1992.PubMed/NCBI
|
|
30
|
Kinoshita S, Adachi W, Sotozono C, Nishida
K, Yokoi N, Quantock AJ and Okubo K: Characteristics of the human
ocular surface epithelium. Prog Retin Eye Res. 20:639–673. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bron AJ, de Paiva CS, Chauhan SK, Bonini
S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, et
al: TFOS DEWS II pathophysiology report. Ocul Surf. 15:438–510.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ablamowicz AF and Nichols JJ: Ocular
surface membrane-associated mucins. Ocul Surf. 14:331–341. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stephens DN and McNamara NA: Altered mucin
and glycoprotein expression in dry eye disease. Optom Vis Sc.
92:931–938. 2015. View Article : Google Scholar
|
|
34
|
Xiao X, He H, Lin Z, Luo P, He H, Zhou T,
Zhou Y and Liu Z: Therapeutic effects of epidermal growth factor on
benzalkonium chloride-induced dry eye in a mouse model. Invest
Ophthalmol Vis Sci. 53:191–197. 2012. View Article : Google Scholar
|
|
35
|
Horikawa Y, Shatos MA, Hodges RR, Zoukhri
D, Rios JD, Chang EL, Bernardino CR, Rubin PA and Dartt DA:
Activation of mitogen-activated protein kinase by cholinergic
agonists and EGF in human compared with rat cultured conjunctival
goblet cells. Invest Ophthalmol Vis Sci. 44:2535–2544. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wickman G, Julian L and Olson MF: How
apoptotic cells aid in the removal of their own cold dead bodies.
Cell Death Differ. 19:735–742. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Sui W, Li Y, Qi X, Wang Y, Zhou Q
and Gao H: Substance P inhibits hyperosmotic stress-induced
apoptosis in corneal epithelial cells through the mechanism of akt
activation and reactive oxygen species scavenging via the
neurokinin-1 receptor. PLoS One. 11:e01498652016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mackay M, Williamson I and Hastewell J:
(A) Cell biology of epithelia. Adv Drug Deliver Rev. 7:313–338.
1991. View Article : Google Scholar
|
|
39
|
Schrader S, Notara M, Beaconsfield M, Tuft
SJ, Daniels JT and Geerling G: Tissue engineering for conjunctival
reconstruction: Established methods and future outlooks. Curr Eye
Res. 34:913–924. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hori Y, Nishida K, Yamato M, Sugiyama H,
Soma T, Inoue T, Maeda N, Okano T and Tano Y: Differential
expression of MUC16 in human oral mucosal epithelium and cultivated
epithelial sheets. Exp Eye Res. 87:191–196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yañez-Soto B, Mannis MJ, Schwab IR, Li JY,
Leonard BC, Abbott L and Murphy CJ: Interfacial phenomena and the
ocular surface. Ocul Surf. 12:178–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Carser JE and Summers YJ: Trichomegaly of
the eyelashes after treatment with erlotinib in non-small cell lung
cancer. J Thorac Oncol. 1:1040–1041. 2006. View Article : Google Scholar
|
|
43
|
Zhang G, Basti S and Jampol LM: Acquired
trichomegaly and symptomatic external ocular changes in patients
receiving epidermal growth factor receptor inhibitors: case reports
and a review of literature. Cornea. 26:858–860. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lane K and Goldstein SM:
Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg.
23:65–66. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Methvin AB and Gausas RE: Newly recognized
ocular side effects of erlotinib. Ophthal Plast Reconstr Surg.
23:63–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Papadopoulos R, Chasapi V and Bachariou A:
Trichomegaly induced by erlotinib. Orbit. 27:329–330. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Braiteh F, Kurzrock R and Johnson FM:
Trichomegaly of the eyelashes after lung cancer treatment with the
epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol.
26:3460–3462. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gillani JA, Iqbal M, Nasreen S, Khan A and
Samad A: Unilateral blindness as a presenting symptom of lung
cancer treated with erlotinib. J Coll Physicians Surg Pak.
18:125–126. 2008.PubMed/NCBI
|
|
49
|
Saif MW and Gnanaraj J: Erlotinib-induced
trichomegaly in a male patient with pancreatic cancer. Cutan Ocul
Toxicol. 29:62–66. 2010. View Article : Google Scholar
|
|
50
|
Kirkpatrick CA, Almeida DR, Hornick AL,
Chin EK and Boldt HC: Erlotinib-associated bilateral anterior
uveitis: Resolution with posterior sub-Tenon's triamcinolone
without erlotinib cessation. Can J Ophthalmol. 50:e66–e67. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Salman A, Cerman E, Seckin D and Kanitez
M: Erlotinib induced ectropion following papulopustular rash. J
Dermatol Case Rep. 9:46–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
